权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A high oxygen capacity cell scaffold for the intravascular bioartifical pancreas (iBAP)

用于血管内生物人工胰腺（iBAP）的高氧容量细胞支架

基本信息

批准号：
9899079
负责人：
Charles Blaha
金额：
$ 29.84万
依托单位：
SILICON KIDNEY, LLC
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-19 至 2023-09-18
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9899079
关键词：
Adult Affect American Anastomosis - action Area Arteries Award Blood Blood Pressure Blood Vessels Blood flow California Catheters Cells Consumption Convection Devices Diffuse Diffusion Drops Emulsions Encapsulated Family suidae Fasting Fluorocarbons Geometry Glucose Grant Healthcare Systems Hemoglobin Hour Housing Immunosuppression Insulin Insulin-Dependent Diabetes Mellitus Islet Cell Islets of Langerhans Transplantation Kidney Kinetics Legal patent Mechanics Membrane Modeling National Institute of Diabetes and Digestive and Kidney Diseases Nutrient Organ Outcome Oxygen Oxygen Consumption Pancreas Patients Permeability Phase Physiological Polymers Production Property Quality of life Safety San Francisco Silicon Small Business Innovation Research Grant Technology Testing Therapeutic immunosuppression Tissue Donors Transplantation Ultrafiltration United States Universities Veins Venous arm base cost density design glycemic control hemocompatibility hypoglycemia unawareness implantation improved innovation islet multidisciplinary nanopore off-patent patient subsets pressure prototype scaffold scale up type I diabetic

项目摘要

PROJECT SUMMARY Type 1 Diabetes (T1D) affects nearly 3 million people in the United States over 20 million people globally. A subset of patients have unstable T1D because they possess poor glycemic control and severe hypoglycemia unawareness. While whole organ pancreas and islet transplantation can cure unstable T1D, these treatments are limited by immunosuppression therapy and scarcity of donor tissue. In contrast, encapsulating islets within an immunoprotecting membrane is a promising approach to eliminate the need for immunosuppression, but previous attempts suffered from low mass transfer rates of oxygen, glucose, and insulin in diffusion-based devices. In order to solve the limitations of diffusion, previous groups tested intravascular convection-based devices and showed some promise, but they provided insufficient ultrafiltration rates to provide sufficient islet oxygenation and glucose-insulin kinetics. In contrast, Silicon Kidney is commercializing the silicon nanopore membrane (SNM), which produces high levels of ultrafiltrate (>10x polymer membranes used in previous ultrafiltrate-based BAP devices) at physiologic blood pressures, providing exceptional convective mass transfer enabling a functional BAP. To further enhance islet oxygenation, perfluorocarbons, which are high oxygen capacity materials, can be incorporated into the islet cell scaffold to mimic the oxygen storage and release properties of hemoglobin by allowing oxygen to be stored during the islet’s low oxygen consumption state (fasting state) and released during the islet’s high oxygen consumption state (post-meal). In this Phase I SBIR project, we will combine the SNM-enabled convection and a perfluorocarbon-based cell scaffold to demonstrate unprecedented islet oxygenation and function, while allowing a reduction in overall device size.

项目总结